Company intelligence / Profile preview
Proacta Inc.
San Diego, California, United Statesprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Proacta developed a pipeline of hypoxia-targeted prodrugs for cancer therapy. Its lead compound PR‑104 showed promising preclinical results in solid tumor models and advanced to clinical trials. The company’s approach aimed to exploit tumor microenvironment features—specifically low oxygen—to selectively activate cytotoxic drugs within tumors while sparing normal tissue. Early clinical data indicated potential benefit for patients with cancers resistant to standard therapies due to tumor hypoxia
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (specifically hypoxia-activated prodrugs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Genentech Inc.Onyx PharmaceuticalsManchester University UKStanford UniversityUniversity of AucklandYakult Honsha for development/commercialization partnership in Japan
Beyond the preview
Go deeper on Proacta Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proacta Inc..